{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:27Z","timestamp":1792785867164,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Netherlands Organisation for Health Research and Development","award":["10070012010001"],"award-info":[{"award-number":["10070012010001"]}],"id":[{"id":"https:\/\/ror.org\/01yaj9a77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the impact of an integrated lifestyle intervention on quality of life and cost-effectiveness in patients undergoing catheter ablation for atrial fibrillation (AF), compared with usual care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Prevention to improve Outcomes of Pulmonary Vein Isolation for AF patients trial randomized patients for their first AF ablation who had at least one modifiable lifestyle-related risk factor between lifestyle intervention and usual care. Quality of life was assessed throughout the trial using the atrial fibrillation effect on quality of life (AFEQT) questionnaire. Treatment burden was evaluated using the treatment burden questionnaire (TBQ). Health state was assessed using the EuroQol 5-dimension (EQ-5D). Quality-adjusted life years (QALYs) were calculated from health states over time and used to calculate incremental cost-effectiveness ratio (ICER). A total of 145 patients participated (74% male; median age 62 years). At 3 months post-ablation, both groups demonstrated significant improvement in AFEQT (P &amp;lt; 0.001), with higher scores in the intervention group (88.9 vs. 80.6; P = 0.026). At 12 months, this difference diminished due to continued improvement in the control group. Throughout the study, TBQ, EQ-5D, and QALYs did not differ significantly between groups. The lifestyle intervention was associated with lower costs at the expense of a small reduction in QALYs, resulting in an ICER of \u20ac16 589 saved per QALY lost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both lifestyle intervention and usual care were associated with marked improvements in AF-specific quality of life following ablation. The lifestyle intervention reduced healthcare costs with minimal impact on health outcomes, supporting structured lifestyle modification as a cost-effective addition to pre-ablation AF care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT05148338<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcag135","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:20:40Z","timestamp":1787570440000},"source":"Crossref","is-referenced-by-count":0,"title":["The effect of integrated lifestyle modification on quality of life and cost-effectiveness in atrial fibrillation ablation: results from the POP-AF RCT"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-4402","authenticated-orcid":false,"given":"Jasper","family":"Vermeer","sequence":"first","affiliation":[{"name":"Department of Cardiology, Catharina Hospital Eindhoven , Michelangelolaan 2, Postbus 1350, 5602 AZ Eindhoven ,","place":["The Netherlands"]},{"name":"Department of Electrical Engineering, Eindhoven University of Technology , Groene Loper 19, Postbus 513, 5600 MB Eindhoven ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-7014","authenticated-orcid":false,"given":"Gijs","family":"van Steenbergen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Catharina Hospital Eindhoven , Michelangelolaan 2, Postbus 1350, 5602 AZ Eindhoven ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-7355","authenticated-orcid":false,"given":"Fabienne","family":"Vervaat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Catharina Hospital Eindhoven , Michelangelolaan 2, Postbus 1350, 5602 AZ Eindhoven ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-7999","authenticated-orcid":false,"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre , P. Debyelaan 25, Postbus 5800, 6202 AZ Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-9203","authenticated-orcid":false,"given":"Dennis","family":"van Veghel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Catharina Hospital Eindhoven , Michelangelolaan 2, Postbus 1350, 5602 AZ Eindhoven ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-3716","authenticated-orcid":false,"given":"Lukas","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Catharina Hospital Eindhoven , Michelangelolaan 2, Postbus 1350, 5602 AZ Eindhoven ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026092112481800300_qcag135-B1","doi-asserted-by":"crossref","first-page":"euae195","DOI":"10.1093\/europace\/euae195","article-title":"Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021","volume":"26","author":"Cheng","year":"2024","journal-title":"Europace"},{"key":"2026092112481800300_qcag135-B2","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010 implications for healthcare planning","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"2026092112481800300_qcag135-B3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jval.2023.12.015","article-title":"The cost of atrial fibrillation: a systematic review","volume":"27","author":"Buja","year":"2024","journal-title":"Value Health"},{"key":"2026092112481800300_qcag135-B4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/europace\/eur194","article-title":"The cost of illness of atrial fibrillation: a systematic review of the recent literature","volume":"13","author":"Wolowacz","year":"2011","journal-title":"Europace"},{"key":"2026092112481800300_qcag135-B5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jacep.2023.12.011","article-title":"Impact of atrial fibrillation burden on health care costs and utilization","volume":"10","author":"Peigh","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"2026092112481800300_qcag135-B6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092112481800300_qcag135-B7","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1111\/jce.14592","article-title":"Quality of life improvements by durable pulmonary vein isolation in patients with atrial fibrillation","volume":"31","author":"Inagaki","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026092112481800300_qcag135-B8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000511048","article-title":"Importance and assessment of quality of life in symptomatic permanent atrial fibrillation: patient focus groups from the RATE-AF trial","volume":"145","author":"Jones","year":"2020","journal-title":"Cardiology"},{"key":"2026092112481800300_qcag135-B9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/pace.14341","article-title":"Quality of life outcomes in cryoablation of atrial fibrillation\u2013a literature review","volume":"44","author":"Vandenberk","year":"2021","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026092112481800300_qcag135-B10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.hroo.2025.03.017","article-title":"Association between quality of life and redo procedures after pulmonary vein isolation in atrial fibrillation patients: data from The Netherlands Heart Registration","volume":"6","author":"van de Kar","year":"2025","journal-title":"Heart Rhythm O2"},{"key":"2026092112481800300_qcag135-B11","first-page":"200344","article-title":"Impact of lifestyle risk factors on atrial fibrillation: mechanisms and prevention approaches\u2014a narrative review","volume":"23","author":"Vermeer","year":"2024","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026092112481800300_qcag135-B12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026092112481800300_qcag135-B13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jacep.2016.12.015","article-title":"Cost-effectiveness and clinical effectiveness of the risk factor management clinic in atrial fibrillation","volume":"3","author":"Pathak","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"key":"2026092112481800300_qcag135-B14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/eurheartj\/ehaf689","article-title":"Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial","volume":"47","author":"Vermeer","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092112481800300_qcag135-B15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00392-023-02185-5","article-title":"Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial","volume":"112","author":"Vermeer","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026092112481800300_qcag135-B16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ahj.2013.04.015","article-title":"Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful?","volume":"166","author":"Dorian","year":"2013","journal-title":"Am Heart J"},{"key":"2026092112481800300_qcag135-B17","doi-asserted-by":"crossref","first-page":"e005358","DOI":"10.1161\/CIRCOUTCOMES.118.005358","article-title":"Defining clinically important difference in the atrial fibrillation effect on quality-of-life score","volume":"12","author":"Holmes","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026092112481800300_qcag135-B18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"2026092112481800300_qcag135-B19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.mayocp.2019.09.004","article-title":"Is my patient overwhelmed?: determining thresholds for acceptable burden of treatment using data from the ComPaRe e-cohort","volume":"95","author":"Tran","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2026092112481800300_qcag135-B20","author":"Ardine de Wit"},{"key":"2026092112481800300_qcag135-B21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s40273-023-01301-7","article-title":"Conducting trial-based economic evaluations using R: a tutorial","volume":"41","author":"Ben","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"2026092112481800300_qcag135-B22","doi-asserted-by":"crossref","first-page":"euae157","DOI":"10.1093\/europace\/euae157","article-title":"Body mass index and pulmonary vein isolation: real-world data on outcomes and quality of life","volume":"26","author":"Vermeer","year":"2024","journal-title":"Europace"},{"key":"2026092112481800300_qcag135-B23","volume-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2015"},{"key":"2026092112481800300_qcag135-B24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12955-022-02057-y","article-title":"Quality of life instruments in atrial fibrillation: a systematic review of measurement properties","volume":"20","author":"Sale","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"2026092112481800300_qcag135-B25","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/europace\/eut055","article-title":"Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation","volume":"15","author":"Hendriks","year":"2013","journal-title":"Europace"},{"key":"2026092112481800300_qcag135-B26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamacardio.2025.4007","article-title":"Aggressive risk factor reduction study for atrial fibrillation implications for ablation outcomes","volume":"10","author":"Pathak","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026092112481800300_qcag135-B27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40273-026-01604-5","article-title":"The cost utility of rhythm control treatment sequences in patients with atrial fibrillation: anti-arrhythmic drugs versus catheter ablation","volume":"44","author":"Huygens","year":"2026","journal-title":"Pharmacoeconomics"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcag135\/70788265\/qcag135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcag135\/70788265\/qcag135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:48:26Z","timestamp":1790009306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article\/doi\/10.1093\/ehjqcco\/qcag135\/8770707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcag135","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"qcag135"}}